Imuno Therapeutics identifies safe targets for cancer immunotherapy. They are redefining targeted immunotherapy by unlocking the vast potential of peptide-HLA (pHLA) antigens. Their proprietary Imuno TACTICS™ platform ensures unparalleled specificity and safety in TCRmimic (TCRm) antibody development, eliminating cross-reactivity while maximizing therapeutic potency. By combining structural epitope mapping with advanced paratope prediction, they engineer next-generation immunotherapies that precisely target intracellular disease antigens – opening new frontiers in oncology and autoimmune therapy.
